Advertisement

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Feb
12
Today In Oncology
PSMA PET/CT-Guided Radiotherapy After Prostatectomy
Rural Populations Face Greater Barriers as Nonmedical Costs Hinder Cancer Clinical Trial Access
FDA Approves Pembrolizumab With Paclitaxel for Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
A New Risk Model for Esophagectomy Draws on the STS National Database
Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo